US-based diagnostic firm HTG Molecular Diagnostics and Japanese pharmaceutical company Daiichi Sankyo have entered into a master service agreement to develop diagnostic tests at the former's VERI/O laboratory.

Initially, the firms will work towards developing a custom assay, using the HTG EdgeSeq technology, to detect approximately 3,000 mRNA targets.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Introduced in 2014, the line of HTG EdgeSeq products are developed to automate samples and target library preparation necessary for next-generation sequencing.

New custom assay will be utilised to produce data from formalin-fixed, paraffin-embedded (FFPE) samples.

Data will then be used by Daiichi Sankyo for the identification of a tumour profiling assay for upcoming studies included in the agreement.

See Also:

HTG president and chief executive officer TJ Johnson said: “We appreciate the confidence Daiichi Sankyo has shown in our HTG EdgeSeq technology and VERI/O laboratory by entering into the master services agreement.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"We are excited to support their important research objectives and the ultimate goal of identifying diagnostic tests that better target therapies for improved patient response."

"We are excited to support their important research objectives and the ultimate goal of identifying diagnostic tests that better target therapies for improved patient response.

“Development work for the initial project is already underway in our laboratory.”

In addition to the assay development, HTG will process several hundred FFPE samples for Daiichi Sankyo.

Intended for exploratory research on new, potential therapeutic biomarkers, the sample processing will leverage the HTG EdgeSeq ALK Plus Assay EU in a research use only mode.